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Abstract
Background: Governments and international donors have partnered to provide free HIV treatment to over 6 million
individuals in low and middle-income countries. Understanding the determinants of HIV treatment costs will help improve
efficiency and provide greater certainty about future resource needs.
Methods and Findings: We collected data on HIV treatment costs from 54 clinical sites in Botswana, Ethiopia, Mozambique,
Nigeria, Uganda, and Vietnam. Sites provided free HIV treatment funded by the U.S. President’s Emergency Plan for AIDS
Relief (PEPFAR), national governments, and other partners. Service delivery costs were categorized into successive six-
month periods from the date when each site began HIV treatment scale-up. A generalized linear mixed model was used to
investigate relationships between site characteristics and per-patient costs, excluding ARV expenses. With predictors at their
mean values, average annual per-patient costs were $177 (95% CI: 127–235) for pre-ART patients, $353 (255–468) for adult
patients in the first 6 months of ART, and $222 (161–296) for adult patients on ART for .6 months (excludes ARV costs).
Patient volume (no. patients receiving treatment) and site maturity (months since clinic began providing treatment services)
were both strong independent predictors of per-patient costs. Controlling for other factors, costs declined by 43% (18–63)
as patient volume increased from 500 to 5,000 patients, and by 28% (6–47) from 5,000 to 10,000 patients. For site maturity,
costs dropped 41% (28–52) between months 0–12 and 25% (15–35) between months 12–24. Price levels (proxied by per-
capita GDP) were also influential, with costs increasing by 22% (4–41) for each doubling in per-capita GDP. Additionally, the
frequency of clinical follow-up, frequency of laboratory monitoring, and clinician-patient ratio were significant independent
predictors of per-patient costs.
Conclusions: Substantial reductions in per-patient service delivery costs occur as sites mature and patient cohorts increase
in size. Other predictors suggest possible strategies to reduce per-patient costs.
Citation: Menzies NA, Berruti AA, Blandford JM (2012) The Determinants of HIV Treatment Costs in Resource Limited Settings. PLoS ONE 7(11): e48726.
doi:10.1371/journal.pone.0048726
Editor: Matthew P. Fox, Boston University, United States of America
Received August 1, 2012; Accepted September 28, 2012; Published November 7, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The PEPFAR ART Costing Project is a PEPFAR-funded public health evaluation (PHE) study led by the U.S. Centers for Disease Control and Prevention
(CDC) and implemented with ICF Macro, in collaboration with the U.S. Agency for International Development (USAID). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests. ICF Macro is a research consulting company that was engaged by the U.S. Centers for Disease
Control to conduct this research. NAM was employed by ICF Macro at the time this study was conducted. There are no patents, products in development, or
marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the
guide for authors.
* E-mail: nick.menzies@gmail.com
Introduction
In 2009, there was $US15?9 billion spent globally on HIV
control, the majority in developing countries [1]. Most of this
funding was devoted to providing care and antiretroviral therapy
for infected individuals, and the expansion of treatment services
has been one of the successes of global HIV control. The emphasis
on treatment within HIV control programs will likely grow as
programs adopt more aggressive antiretroviral therapy (ART)
initiation criteria [2] and as evidence accumulates about the
substantial prevention benefits resulting from HIV treatment [3].
Despite these advances, treatment programs face constrained
budgets, with both domestic and external HIV spending under
increasing pressure.
Obtaining better evidence on HIV treatment costs is a priority
of major donors such as the President’s Emergency Plan for
AIDS Relief (PEPFAR), the Global Fund and the Gates
Foundation [4,5]. Understanding the costs of HIV treatment
serves two important functions. The first is to plan for future
expenditure requirements: as HIV treatment requires lifelong
care, initiation of patients on treatment implies a resource
commitment both in the present and future. Gaining greater
certainty about resource requirements puts funders in a better
position to make long-term commitments about program targets.
The second function is to suggest strategies for improving the
efficiency of HIV treatment programs. Progressive gains have
been made in driving down the costs of antiretroviral drugs, with
a first-line regimen that cost $1,200 in 2001 now available for
$120 [6,7]. While antiretroviral drug (ARV) costs historically
consumed the majority of a treatment program’s budget this is
no longer the case, with non-ARV costs–personnel, facilities,
laboratory tests–consuming a progressively larger proportion of
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dropped. Understanding these service delivery costs is important
as treatment programs seek further efficiencies.
Evidence on patient-level determinants of treatment costs has
been accumulating, with disease severity [8], drug regimen [9],
route of infection and sociodemographic characteristics [10] all
shown to produce differences in annual treatment costs. Less
evidence is available on programmatic determinants of treatment
costs, despite large variation in average cost observed between
providers [11,12]. Part of the reason for this evidence gap is
heterogeneity in costing methods between studies: as most studies
only include one or a small number of sites, data must be pooled
across studies to gain sufficient power to investigate site-level
variables, yet variation in costing approach between studies
hampers such pooled analyses. An increasing number of modeled
analyses have provided insight into the consequences of policies
such as ART initiation criteria [13–15], first-line drug regimens
[16], and laboratory tests [14,17], yet by their design these
analyses only address cost differentials resulting from the frequency
with which individual services are provided (e.g., inpatient days,
CD4 count tests), and cannot provide information on the factors
determining the unit costs of these services. Some modeled
analyses have attempted to describe the cost functions of scaling up
HIV treatment programs, but are hampered by the relative lack of
empirical evidence to parameterize these functions [18,19]. A
small number of empirical studies in South Africa have
investigated site-level cost determinants, finding input prices
[20], patient volume [20], site maturity [21], staffing approach
[22], and location [23] all to influence average treatment costs, yet
these findings are necessarily tentative given the small sample of
sites–between one and four–included in these studies.
This study makes use of a unique dataset on HIV treatment
costs drawn from 54 HIV treatment sites across six countries,
collected using consistent methods and covering a comprehensive
range of HIV treatment services [12,24]. The common method-
ology allows valid comparisons across sites, and across time
periods within each site. We used these data to investigate site-level
determinants of the service delivery costs of HIV treatment.
Methods
This analysis utilizes a dataset of HIV treatment costs collected
from 54 HIV treatment sites across six countries. These data were
collected as part of a multicountry costing study conducted in
Botswana, Ethiopia, Nigeria, Uganda and Vietnam (9 sites per
country), as well as a more recent study conducted in Mozambique
(11 sites) that utilized the same costing methods. Two Ugandan
sites were excluded from the analysis due to a lack of adequate
patient volume data. All sites included in this dataset were out-
patient clinics providing free treatment for HIV-infected individ-
uals, and all relied on resource support from a mix of funders,
including PEPFAR. Most sites were attached to a larger health
facility in some way, with only 8 out of 54 sites being stand-alone
clinics. Data collection adopted a comprehensive provider
perspective, including the costs of personnel, drugs and other
clinical supplies, laboratory supplies, other supplies, travel, utilities
and building costs, training and supervision, equipment and
renovation/construction. This perspective included the costs of
any regular technical assistance supervision, M&E, and manage-
ment support to the site, but excluded higher-level overhead costs
incurred at a regional or central-level which could not be
attributed directly to the site. Data were collected with a modified
macro-costing approach, whereby total site-level costs were
estimated for each patient type. These totals were divided by
patient volume (no. patient-years) for each patient type to estimate
the average cost per patient. For each site, data were collected
retrospectively to cover the full duration of site activities from the
time when sites began scaling up to provide HIV treatment to the
time of data collection. Standardized data collection tools were
used to extract information from accounting records, prescribing
logs, equipment inventories, and routine reports, as well through
structured interviews with site personnel. Individual cost items
were coded to allow disaggregation by program activity, budget
category and funder, and costs were broken into successive 6-
month periods for analysis. Cost analyses included all patients
receiving HIV treatment at study sites, including both ART and
pre-ART patients, with data on patient volume drawn from
routine program reporting records. By the end of the evaluation, a
total of 76,416 ART patients and 95,538 pre-ART patients were
receiving HIV care at study sites. The studies which collected these
data received institutional review board clearance and data
collection was conducted with the approval of the Ministry of
Health in each country. Further detail on data collection methods
is reported in Menzies, et al [12].
The subject of the analysis is the annualized per-patient cost of
service delivery, excluding ARV expenditures. The costs of ARVs
were excluded from the analysis as these can be better explained
by global drug commodity trends, regimen distributions and
national price levels, and are not principally driven by site-level
factors. Following standard practice, primary data on resource use
were converted to economic costs, with investments annualized
over their useful life at a 3% discount rate, and donated items
valued at market prices [25]. Overheads and shared costs were
allocated by direct allocation [26] and the opportunity costs of
existing infrastructure were estimated as the equivalent rental cost.
All costs were converted to U.S. dollars using prevailing inter-bank
exchange rates and inflated to current prices. Results are reported
in 2010 U.S. dollars.
The duration for which data were available varied between
sites, from 6 to 36 months, providing between 1 and 6 six-month
periods for analysis (mean =3?0 periods per site). In addition, cost
data were available for five distinct patient types: pre-ART
patients, newly initiated adult ART patients, established adult
ART patients, newly initiated pediatric ART patients, and
established pediatric ART patients. Pediatric and adult patients
were those aged 0–15 and .15 years respectively, and newly
initiated and established patients were those who had received
ART for 0–6 and .6 months, respectively.
Possible explanatory variables were divided into distal determi-
nants and proximal determinants. Distal determinants described
general features of the site (i.e., location, health system level, type
of administration) that might play a role in determining the
operating characteristics of the site and thus influence costs.
Proximal variables described site operating characteristics (i.e., site
maturity, patient volume, frequency of clinical and laboratory
monitoring, comprehensiveness of care services provided, staffing
structure, percentage of spending devoted to management and
administration, and log per-capita GDP as an indicator of price
levels). The first part of the analysis focuses on proximal
determinants, the second part focuses on distal determinants.
Table 1 provides descriptions for explanatory variables included in
the analysis.
The dataset has a complex structure and a generalized linear
mixed model (GLMM) was adopted for the analysis, with a log link
function, and random effect terms used to account for clustering at
country, site, and time period level. Fixed effects were also
included for each patient type. The dataset includes a total of 692
observations, however the effective sample size is smaller than this
Determinants of HIV Treatment Costs
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model was estimated using Markov Chain Monte Carlo (MCMC)
simulation implemented with R statistical computing software
[29,30].
The estimates produced by the GLMM regression relate to log-
transformed costs, and care must be taken when interpreting
coefficient values. Individual regression coefficients have a non-
linear relationship with the raw per-patient cost, such that a unit
increase in a particular predictor xi (with regression coefficient bi)
results in an average per-patient cost that is 100  ebi 
% of its
original value, all other values being held equal. For this reason a
series of first differences was calculated to investigate the
implications of changes in site characteristics for the average
per-patient cost, by simulating the absolute and percentage change
in per-patient costs resulting from the change in one explanatory
variable, all other variables being held at their mean value.
Direct retransformation of logged estimates can yield biased
results [31,32], so estimates of the absolute per-patient cost were
derived by sampling from the posterior distribution of the
regression coefficients and taking the mean of the exponent of
these sampled values, with 95% confidence intervals calculated as
the 2?5
th and 97?5
th percentiles of the exponentiated values.
A similar approach was used to calculate estimates of the annual
per-patient cost for each patient type. For a given patient type, we
set the patient type dummy variables to their appropriate value for
that patient type, as well as setting the clinic visit frequency and
CD4 count frequency variables to their subgroup-specific means,
as both of these variables differ by patient type. All other variables
were set to their global mean (mean across all observations), and
the mean and confidence intervals for the annual per-patient cost
calculated by simulating from the posterior distribution of the
regression coefficients, as described above. To calculate total per-
patient costs (including ARVs) we used current drug prices and
regimen distributions for each country derived from the WHO
Global Price Reporting Mechanism [33], with a 8.3% mark-up for
transportation and other supply-chain management costs [12].
Exploratory analyses revealed that the size of the treatment
program (as measured by patient volume) was strongly related to
per-patient costs, with larger sites exhibiting substantially lower
costs than smaller sites when controlling for other covariates. As a
consequence, the per-patient cost calculated as an average across
sites will be larger than the same statistic calculated as an average
across patients. For an audience interested in budgeting and
resource planning, it is intuitive that total funding requirements
can be calculated by multiplying total patient volume by some
measure of the average per-patient cost. For this purpose
calculating the average cost across sites will give a biased
(over)estimate of total costs, and the ‘patient-average’ cost alone
is appropriate. For this reason, all dollar-valued results were
calculated using this patient-average approach. This approach
differs from prior analyses, which gave equal weight to each site
when calculating summary statistics [12].
It was hypothesized that the effect of the distal determinants
(location, health system level, type of administration) on per-
patient costs would be mediated, in whole or in part, by their
influence on the proximal determinants. For this reason three
different model specifications were used to investigate the
influence of the distal determinants. First, a parsimonious model
was fit including only the distal determinants. A second model was
then fit including these variables as well as variables relating to site
maturity and patient volume. Finally, a full model was fit including
the distal determinants as well as all proximal determinants. All
regression models were implemented using the GLMM framework
described above.
Table 1. Variable descriptions.
Variable Name Description
Proximal Determinants
Site Maturity Number of months since sites began scaling-up to provide HIV treatment, calculated from the midpoint of each costing period.
Patient Volume Average number of patients (combined ART + pre-ART) supported by the site during the costing period, in 1,000 s.
Clinic Visit Frequency Average number of clinic visits (per patient) during 6-month period (differs by patient type).
CD4 Count Frequency Average number of CD4 count tests (per patient) during 6-month period (differs by patient type).
Comprehensiveness of Care Index of the comprehensiveness of patient care, the sum of the number of additional care services provided at the treatment site,
from the following list of priority services: onsite TB treatment, isoniazid preventive therapy for TB, STI treatment, cotrimoxazole
prophylaxis, provision of insecticide treated bednets, provision of water sanitation products, psychosocial support, pain
management, end of life care, availability of viral load testing, and community follow-up of patients missing appointments. In our
sample the index varied from 2 to 10 with a mean of 6?4.
Clinician:Patient Ratio Number of full-time equivalent (FTE) clinicians per 1,000 patients. Clinician includes physicians, nurses, clinical officers, medical
assistants, clinical counselors, and other non-physician clinicians.
Doctor:Clinician Ratio FTE physicians as a percentage of all clinicians, included to investigate task-shifting issues.
Pct Mgmt/Admin Percent of total resources devoted to site-level management and administration activities (c.f. direct patient care).
Log Per Capita GDP Natural log of annual per-capita GDP in U.S. dollars [27], as an indicator of local price levels and complexity of resource use [28].
Patient Type Indicator variables for patient type, including pre-ART, established adult ART (reference category), newly initiated adult ART,
established pediatric ART, and newly initiated pediatric ART.
Distal Determinants
Location Indicator variables for site location, dichotomized into urban and non-urban (reference category). The sample included 39 urban
sites and 15 non-urban sites.
Health System Level Indicator variables for health system level, including primary (reference category), secondary, and tertiary sites. The sample included
10 primary sites, 16 secondary sites and 28 tertiary sites.
Type of Administration Indicator variables for type of administration, dichotomized into government and NGO/FBO (reference category). The sample
included 46 government sites and 8 NGO/FBO sites.
doi:10.1371/journal.pone.0048726.t001
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Crude Site-Level Costs
The cost per patient varied widely in the sample, with
annualized costs for adult established ART patients ranging from
$36 to $4,374, with an interquartile range of $154–$586 and a
median of $322.
Proximal Determinants of Per-Patient Costs
Table 2 presents coefficients and measures of uncertainty for the
regression of the logged per-patient cost against the proximal
explanatory variables described in Table 1.
Most proximal determinants show a statistically significant
relationship with per-patient treatment costs. Greater site matu-
rity, higher patient volume, less frequent clinical and laboratory
monitoring, less clinical staff per patient, and lower price levels
(proxied by log per-capita GDP) are all independently associated
with lower per-patient costs. The comprehensiveness of care and
the fraction of resources devoted to site-level management and
administration are both positively associated with per-patient
costs, though this relationship is only marginally significant. The
ratio of doctors to other clinical staff (relevant to task-shifting
efforts) does not appear to be associated with per-patient costs,
though given the small sample size it is possible that this analysis
would not identify an effect of small magnitude, if present.
The magnitude of the regression coefficients are difficult to
interpret directly and for this reason a series of comparisons is
presented in Table 3 describing the impact of various program
changes on per-patient costs.
Patient volume and site maturity both have a substantial effect
on per-patient costs, with an increase in each associated with
considerably lower costs. A squared term was included in the
regression equation for each of these variables. Both of these
squared terms are positive, and the implications of this are
presented in Figure 1, which shows the negative and convex
relationship between per-patient costs and site maturity (first
panel), and per-patient costs and patient volume (second panel),
holding all other variables constant at their mean values.
Per-patient costs are estimated to increase by approximately
one-third for each one-unit increase in log per-capita GDP
(equivalently, costs increase by 22% (4–41%) for every doubling of
per-capita GDP). The implications of this in terms of absolute per-
capita GDP are shown in Figure 2, which also shows the estimated
mean and confidence interval for the per-patient cost in each
country. These country-level results can be combined with current
drug prices and regimen distributions for each country [33] to
produce estimates of total per-patient costs for established adult
ART patients on first-line regimens: $546 for Botswana, $261 for
Ethiopia, $294 for Mozambique, $425 for Nigeria, $378 for
Uganda, and $363 for Vietnam. The average across all countries
was $365. The percentage of these totals attributable to non-ARV
service delivery ranged from 51–71% across the 6 countries, with
an overall average of 61%.
Figure 3 presents estimates of the per-patient cost for each
patient type, averaged across all six countries. Newly initiated
ART patients consume substantially more resources than estab-
lished ART patients, and pre-ART patients substantially less.
While the confidence intervals in the figure overlap, these
differences are statistically significant, with established adult
ART per-patients costs 26% (95% CI: 19–33%) higher than
pre-ART per-patient costs, and newly initiated adult ART per-
patient costs 58% (95% CI: 50%–67%) higher than established
adult ART patients. Similarly, newly initiated pediatric ART per-
patient costs are 56% (95% CI: 47%–64%) more costly than
established pediatric ART patients, while the cost differences
between adult and pediatric ART patients are small and non-
significant.
Distal Determinants of Per-Patient Costs
Three regression models were fit to investigate the impact of
distal determinants (urban vs. rural location, health system level,
and government vs. NGO/FBO) on per-patient costs: a parsimo-
nious regression model just containing the three distal determi-
nants, a second model containing these variables as well as site
maturity and patient volume covariates, and a full model including
all distal and proximal determinants. The results for these three
regressions are shown in Table 4.
In none of these analyses do any of the distal determinants show
a clear significant relationship with per-patient costs. While prior
beliefs suggest that primary sites are more expensive than
Table 2. GLMM regression of annual per-patient HIV treatment costs on proximal cost determinants.
{
Coefficient Std. Error 95% CI P-Value
{
Site Maturity 20?055 0?011 (20?076, 20?035) ,0?001***
Site Maturity Sq. 0?0008 0?0002 (0?0004, 0?0013) ,0?001***
Patient Volume 20?166 0?057 (20?277, 20?057) 0?004**
Patient Volume Sq. 0?006 0?003 (0?001, 0?011) 0?01*
Clinic Visit Frequency 0?037 0?006 (0?024, 0?048) ,0?001***
CD4 Count Frequency 0?186 0?019 (0?149, 0?224) ,0?001***
Comprehensiveness of Care 0?094 0?055 (20?009, 0?211) 0?09
Clinician:Patient Ratio 0?010 0?002 (0?007, 0?014) ,0?001***
Doctor:Clinician Ratio 20?551 0?489 (21?548, 0?360) 0?26
Pct Mgmt-Admin 0?013 0?008 (20?002, 0?029) 0?10
Log Per-Capita GDP 0?280 0?113 (0?047, 0?490) 0?02*
Intercept 3?439 0?845 (1?770, 5?037) 0?003**
{HIV treatment costs represent economic costs of site-level service delivery in 2010 US dollars, excluding ARVs and national/regional overhead costs. Regression model
also included dummy variables for patient type (reference = established adult ART patients), coefficients not shown.
{ ’***’denotes p,0?001, ’**’denote p,0?01, and
’*’denotes p,0?05.
doi:10.1371/journal.pone.0048726.t002
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these data. The only set of results which approach statistical
significance are in the regression controlling for site maturity and
patient volume (middle panel in Table 4), where the estimates
suggest that for a site of comparable size and maturity, primary
sites might actually be cheaper. It could be that the economies of
Table 3. Change in annual per-patient cost for established adult ART patients associated with changes in individual cost
determinants.
{
Absolute Change Percentage Change P-Value
{
Site matures from 0 to 12 months 2$157 (2$271, -$71) 241% (252%, 228%) ,0?001***
Site matures from 12 to 24 months 2$55 ($–92, -$25) 225% (235%, 215%) ,0?001***
Patient volume increases from 500 to 5,000 patients 2$166 (2$287, -$57) 243% (263%, 218%) 0?004**
Patient volume increases from 5,000 to 10,000 patients 2$58 (2$92, -$16) 228% (247% 26?3%) 0?02*
One additional clinic visit per year $4?12 ($2?50, $6?12) 1?8% (1?3%, 2?4%) ,0?001***
One additional CD4 test per year $22 ($15, $31) 9?7% (7?7%, 12%) ,0?001***
One additional service in care package $22 (-$3?68, $52) 10% (21?7%, 23%) 0?09
One additional clinician per 1,000 patients $2?35 ($1?42, $3?55) 1?1% (0?7%, 1?4%) ,0?001***
10 percentage point increase in the fraction of site
resources going to mgmt and admin
$32 (-$5?46, $78) 14% (22?5%, 33%) 0?10
Annual per-capita GDP rises from $500 to $1,500 $65 ($13, $122) 37% (6?1%, 73%) 0?02*
Annual per-capita GDP rises from $1,500 to $5,000 $104 ($15, $231) 41% (6?7%, 83%) 0?02*
{HIV treatment costs represent economic costs of site-level service delivery in 2010 US dollars, excluding ARVs and national/regional overhead costs. Changes in per-
patient costs calculated from a regression of per-patient costs against proximal cost determinants. Each comparison shows the consequence of change in a single
determinant, holding all other determinants at their mean values.
{P-values represent two-sided test for difference from zero, ’***’denotes p,0?001, ’**’denotes
p,0?.01, and ’*’denotes p,0?05.
doi:10.1371/journal.pone.0048726.t003
Figure 1. Change in annual per-patient cost for established adult ART patients as a function of site maturity and patient volume.
Panel A shows annual HIV treatment cost as a function of site maturity. Panel B shows annual HIV treatment cost as a function of patient volume. HIV
treatment costs represent annual economic costs of site-level service delivery in 2010 US dollars, excluding ARVs and national/regional overhead
costs. Changes in per-patient costs calculated from a regression of per-patient costs against proximal cost determinants. Each panel shows the
consequence of change in a single determinant, holding all other determinants at their mean values.
doi:10.1371/journal.pone.0048726.g001
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offset by a more expensive care model, as secondary and tertiary
sites grouped together are positively associated with the frequency
of clinic visits (p=0?31), frequency of CD4 tests (p=0?05), number
of different care services provided (p,0?001), and the clinician:-
patient ratio (p=0?04), when controlling for all other cost
determinants. While the small sample size means that non-
significant findings must be interpreted with caution, it appears
that these distal determinants–location, health system level, and
type of administration–may have a weak relationship with per-
patient costs.
Discussion
The global funding devoted to HIV treatment dwarfs resources
available for many other health concerns, but the goal of providing
treatment access to all those in need has not yet been achieved.
With constrained budgets, treatment programs must better
understand the costs of care and identify opportunities to improve
efficiency, in order to continue expanding treatment access. The
results of these analyses reveal a number of possible paths to lower
per-patient costs. The largest reductions in per-patient costs will
likely be those that will be obtained with the least effort, as
programs mature and treatment cohorts grow with the continued
enrollment of patients. Given the strong relationship between
program size and the per-patient cost, strategies that increase
access through smaller sites may be more resource-intensive than a
more centralized approach. While a focus on smaller sites may be
important for achieving health sector goals of geographic equity
and improved access in rural locations, these goals must be
weighed against the additional cost. It is a notable finding of this
analysis that, when controlling for patient volume and site
maturity, primary-level sites appear to be no more expensive than
sites at higher levels of the health system, and possibly less
expensive as a result of a more-limited package of care. Other cost
determinants are more amenable to policy intervention, such as
extending the interval for clinical follow-up and laboratory
monitoring of established patients, optimization of the care
package accompanying ART, and standardizing staffing intensity.
Each of these factors was found to make small but non-trivial
contributions to total treatment costs.
When considering the policy applications of these findings, it is
important to note that the outcome used in this analysis–the
annual per-patient cost–does not capture the quality of care or
extent of the health benefits enjoyed by patients receiving that
care. As such, actions directed at reducing the per-patient cost
must consider the possible impacts on quality and patient
outcomes. The fact that universal access targets have not been
reached except in a few settings provides strong motivation to treat
as many patients as possible with the funding available, yet there
will be a point at which the gains in terms of greater coverage will
be more than offset by the harm to patient outcomes (if treatment
quality falls) and program sustainability (if staff are overworked or
infrastructure used beyond capacity).
The comprehensiveness of care index give an overall summary
of how the number of additional care services contribute to total
cost, yet does not distinguish between individual components of
the care package, which may vary considerably in their costs and
Figure 2. Change in annual per-patient cost for established adult ART patients as a function of per-capita GDP. HIV treatment costs
represent economic costs of site-level service delivery in 2010 US dollars, excluding ARVs and national/regional overhead costs. Changes in per-
patient costs calculated from a regression of per-patient costs against proximal cost determinants. The plot shows the consequence of changes in
per-capita GDP, holding all other determinants at their mean values. Overplotted country-level estimates: ETH=Ethiopia, MOZ=Mozambique,
UGA=Uganda, VIE=Vietnam, NIG=Nigeria, BOT=Botswana.
doi:10.1371/journal.pone.0048726.g002
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inexpensive additions to the care package can produce health
gains that more than justify their expense [34,35]. For this reason
the results of this analysis point to possible approaches for reducing
costs but do not provide sufficient information to judge the cost-
effectiveness of individual components of the care package.
Figure 3. Average annual per-patient HIV treatment costs, by patient type. HIV treatment costs represent economic costs of site-level
service delivery in 2010 US dollars, excluding ARVs and national/regional overhead costs. Cost estimates calculated from a regression of per-patient
costs against proximal cost determinants. In figure, diamond signifies point estimate, length of bars signifies 95% confidence interval.
doi:10.1371/journal.pone.0048726.g003
Table 4. GLMM regression of annual per-patient HIV treatment costs against distal cost determinants, with three model
specifications.
{
Coefficient Std. Error 95% CI P-Value
{
Regression model includes distal determinants
{ plus patient type fixed effects (coefficients not shown)
Secondary level 0?17 0?32 (20?47, 0?77) 0?60
Tertiary level 20?20 0?31 (20?78, 0?43) 0?50
Urban 20?01 0?25 (20?51, 0?45) 0?99
NGO/FBO 20?24 0?34 (20?92, 0?41) 0?51
Regression model includes distal determinants, plus patient type fixed effects, site maturity and patient volume (coefficients not shown)
Secondary level 0?56 0?32 (20?07, 1?18) 0?08
Tertiary level 0?38 0?33 (20?24, 1?05) 0?24
Urban 20?08 0?26 (20?59, 0?44) 0?74
NGO/FBO 20?14 0?34 (20?83, 0?50) 0?67
Regression model includes distal determinants, plus all proximal determinants included in earlier regressions (coefficients not shown)
Secondary level 0?18 0?29 (20?42, 0?72) 0?52
Tertiary level 0?32 0?30 (20?24, 0?93) 0?29
Urban 20?11 0?24 (20?60, 0?35) 0?61
NGO/FBO 20?11 0?31 (20?71, 0?52) 0?72
{HIV treatment costs represent economic costs of site-level service delivery in 2010 US dollars, excluding ARVs and national/regional overhead costs. P-values represent
two-sided test for difference from zero, ’***’denotes p,0?001, ’**’denotes p,0?01, and ’*’denotes p,0?05.
{Distal determinants include health system level (primary vs.
secondary vs. tertiary), location (urban vs. non-urban), and type of administration (government vs. NGO/FBO).
doi:10.1371/journal.pone.0048726.t004
Determinants of HIV Treatment Costs
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e48726Additional research is needed to inform the question of how
clinical outcomes might be affected by competing operational
approaches or packages of care.
The results of this analysis provide an empirical basis for
estimating the resource needs for supporting HIV treatment
programs in the future, allowing analysts to begin to specify cost
functions that are sensitive to program scale, maturity and other
operating characteristics. While a second-best to empirical data
collected within a given HIV treatment program, the relationship
between per-capita GDP and per-patient costs identified in this
analysis provides a method for creating approximate cost estimates
for settings where a costing has not yet been undertaken or where
the treatment program is still in its nascent stages. For such
resource needs projections, it will be important to consider two
cost categories excluded from this analysis: the cost of antiretro-
viral medications, and the costs of program administration
incurred at regional and national-level. Each of these cost
categories will represent a non-trivial fraction of the overall cost
of a treatment program, and both will likely be governed by a set
of determinants different from those assessed in this analysis. In the
case of ARVs, the per-patient cost will be sensitive to drug prices
and regimen distributions. As both of these factors can change
rapidly, cost projections will need to be based on real-time data,
and ideally account for changes in these factors that might be
anticipated over the timeframe of the cost projections. Higher-
level program administration costs will likely be subject to maturity
and scale effects as well as the interactions of major program
funders, but as yet little is known about these costs and they
represent an important subject for future research.
Some limitations should be noted. The analysis does not include
patient time-and-travel costs, which may be higher under a
centralized scale-up approach. Also excluded from this analysis is
the epidemic impact of infections averted through treatment, and
the associated savings that would accrue from the averted
infections. Similarly, productivity gains that result from improved
health of patients, and averted HIV-associated orphanhood from
reduction in AIDS deaths are also not included. Consideration of
these broader societal costs and benefits might influence decisions
about optimal treatment scale-up.
As programs gain more evidence about the cost and benefits of
different clinical approaches, they will be better positioned to focus
on high-impact services and streamline other aspects of care,
freeing up resources to support larger patient cohorts. In this way
the benefits of improved efficiency will be measured in the number
of additional patients who can be enrolled on treatment, and
through the resulting impact on HIV patients’ health, their
families’ welfare, and the reduction in new HIV infections.
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